Total submissions: 7
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000862805 | SCV001003359 | likely benign | Charcot-Marie-Tooth disease type 2 | 2025-01-01 | criteria provided, single submitter | clinical testing | |
| Personalized Diabetes Medicine Program, |
RCV001174399 | SCV001337537 | uncertain significance | Monogenic diabetes | 2018-01-05 | criteria provided, single submitter | research | ACMG criteria: PM4 (nonframeshift)=VUS |
| Ambry Genetics | RCV002345950 | SCV002653293 | likely benign | Inborn genetic diseases | 2021-11-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| New York Genome Center | RCV002468078 | SCV002764375 | uncertain significance | Congenital generalized lipodystrophy type 2 | 2022-02-10 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV003442125 | SCV004167963 | uncertain significance | not provided | 2023-10-13 | criteria provided, single submitter | clinical testing | In-frame deletion of 1 amino acid in a non-repeat region; In silico analysis supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Clinical Genomics, |
RCV002468078 | SCV004698138 | uncertain risk allele | Congenital generalized lipodystrophy type 2 | criteria provided, single submitter | research | Potent mutations in BSCL2 gene are associated with Congenital generalized lipodystrophy, type 2, which can present with insulin resistance, fatty liver and diabetes.However, the role of this particular variant rs556562410 of Congenital Generalized Lipodystrophy type 2 remains uncertain | |
| Mayo Clinic Laboratories, |
RCV003442125 | SCV005412348 | uncertain significance | not provided | 2023-12-11 | criteria provided, single submitter | clinical testing | BS1, PM4 |